Form 4 for UTHR UNITED THERAPEUTICS Corp
Accepted 2025-12-16 00:00:00 ET · period of report 2025-12-15 · accession 0001636178-25-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2025-12-16 | 2025-12-15 | UTHR | EDGEMOND JAMES | CFO AND Treas | S - Sale+OE | $495.36 | -3,517 | 9,018 | -28% | -$1.74M |
| DT | 2025-12-16 | 2025-12-15 | UTHR | EDGEMOND JAMES | CFO AND Treas | M - OptEx | $146.03 | +3,517 | 11.7K | +43% | +$513.6K |
| DT | 2025-12-16 | 2025-12-15 | UTHR | EDGEMOND JAMES | CFO AND Treas | M - OptEx | $0.00 | -3,517 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-15 | S | D | 561 | $493.70 | 10,098 | D | — | — | (F5) This transaction was executed in multiple trades at prices ranging from $493.35 to $494.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2025-12-15 | S | D | 360 | $495.02 | 9,738 | D | — | — | (F6) This transaction was executed in multiple trades at prices ranging from $494.52 to $495.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2025-12-15 | S | D | 520 | $495.90 | 9,218 | D | — | — | (F7) This transaction was executed in multiple trades at prices ranging from $495.52 to $496.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Common | Common Stock | 2025-12-15 | S | D | 160 | $491.53 | 11,499 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $491.19 to $491.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Common | Common Stock | 2025-12-15 | S | D | 395 | $498.09 | 8,623 | D | — | — | (F9) This transaction was executed in multiple trades at prices ranging from $497.60 to $498.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 6 | Common | Common Stock | 2025-12-15 | S | D | 240 | $499.31 | 8,383 | D | — | — | (F10) This transaction was executed in multiple trades at prices ranging from $498.88 to $499.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 7 | Common | Common Stock | 2025-12-15 | S | D | 241 | $500.30 | 8,142 | D | — | — | (F11) This transaction was executed in multiple trades at prices ranging from $499.92 to $500.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 8 | Common | Common Stock | 2025-12-15 | M | A | 3,517 | $146.03 | 11,659 | D | — | — | (F2) The amount of common stock beneficially owned by the Reporting Person in the Reporting Person's Form 4s filed November 5, 12 and 18, 2025 did not include 24 shares acquired by the Reporting Person on September 4, 2025 under the United Therapeutics Corporation Stock Purchase Plan, which error caused the reporting person's common stock ownership to be underreported by 24 shares on such Form 4s. The amount of common stock beneficially owned by the Reporting Person in this Form 4 includes such shares. |
| 9 | Common | Common Stock | 2025-12-15 | S | D | 840 | $492.81 | 10,659 | D | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $492.28 to $493.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 10 | Common | Common Stock | 2025-12-15 | S | D | 200 | $496.97 | 9,018 | D | — | — | (F8) This transaction was executed in multiple trades at prices ranging from $496.59 to $497.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 11 | Derivative | Stock Option | 2025-12-15 | M | D | 3,517 | $0.00 | 0 | D | $146.03 · 2020-03-15 to 2027-03-15 | 3,517 Common Stock |